BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCDA BioCardia

Trading 03-27 14:09:56 EDT

1.19

+0.01

+0.85%

High1.23	Low1.16	Vol23.66K
Open1.20	D1 Closing1.18	Amplitude5.92%
Mkt Cap13.02M	Tradable Cap4.82M	Total Shares10.94M
T/O27.92K	T/O Rate0.58%	Tradable Shares4.05M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":1.19,"timestamp":1774634466485,"preClose":1.18,"halted":0,"volume":23655,"delay":0,"changeRate":0.00847457627118645,"floatShares":4052600,"shares":10940400,"eps":-1.234148,"marketStatus":"Trading","change":0.01,"latestTime":"03-27 14:09:56 EDT","open":1.2,"high":1.2299,"low":1.16,"amount":27923.334220499997,"amplitude":0.059237,"askPrice":1.21,"askSize":100,"bidPrice":1.17,"bidSize":101,"shortable":3,"etf":0,"ttmEps":-1.234148,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774641600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.18,"preHourTrading":{"tag":"盘前","latestPrice":1.24,"preClose":1.18,"latestTime":"09:06 EDT","volume":33,"amount":41.2094958,"timestamp":1774616802772,"change":0.06,"changeRate":0.050847,"amplitude":0.007797},"postHourTrading":{"tag":"盘后","latestPrice":1.1626,"preClose":1.18,"latestTime":"17:37 EDT","volume":230,"amount":268.5144,"timestamp":1774561033112,"change":-0.0174,"changeRate":-0.014746,"amplitude":0.014746},"volumeRatio":0.853766,"impliedVol":0.046,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BCDA/wiki","defaultTab":"wiki","newsList":[{"id":"2622890512","title":"BioCardia President and CEO Peter Altman acquires common shares; purchases total $1,110","url":"https://stock-news.laohu8.com/highlight/detail?id=2622890512","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622890512?lang=en_us&edition=fundamental","pubTime":"2026-03-27 08:06","pubTimestamp":1774569979,"startTime":"0","endTime":"0","summary":"BioCardia reported open-market purchases of common stock by Peter Altman, President and CEO and a director.Altman acquired 900 shares at prices of USD 1.24 and USD 1.22.Following the transactions, he beneficially owned 274,766 shares directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL1VX8BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia President and CEO Peter Altman acquires common shares; purchases total $1,110","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2622907302","title":"Alliance Global Partners Sticks to Their Buy Rating for BioCardia (BCDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622907302","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622907302?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:16","pubTimestamp":1774440971,"startTime":"0","endTime":"0","summary":"In a report released today, James Molloy from Alliance Global Partners reiterated a Buy rating on BioCardia, with a price target of $6.00. Molloy c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-sticks-to-their-buy-rating-for-biocardia-bcda-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/alliance-global-partners-sticks-to-their-buy-rating-for-biocardia-bcda-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA"],"gpt_icon":0},{"id":"2622016685","title":"BioCardia Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622016685","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622016685?lang=en_us&edition=fundamental","pubTime":"2026-03-25 05:38","pubTimestamp":1774388301,"startTime":"0","endTime":"0","summary":"BioCardia Inc reports results for the quarter ended December 31 - Earnings SummaryBioCardia Inc BCDA.OQ reported a quarterly adjusted loss of 6 cents per share for the quarter ended December 31, highe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C2WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2622013835","title":"BioCardia Q4 EPS $(0.06) Beats $(0.17) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013835","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013835?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:13","pubTimestamp":1774383237,"startTime":"0","endTime":"0","summary":"BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.17) by 64.71 percent. This is a 76 percent increase over losses of $(0.25) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51444648/biocardia-q4-eps-0-06-beats-0-17-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia Q4 EPS $(0.06) Beats $(0.17) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"gpt_icon":0},{"id":"2622018271","title":"Press Release: BioCardia Reports 2025 Business Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622018271","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622018271?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:05","pubTimestamp":1774382700,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., March 24, 2026  -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2025 and filed its annual report on Form 10-K with the Securities and Exchange Commission.The Company will host a corporate update conference call today, on Tuesday, March 24, 2026, at 4:30 PM ET, in which it will discuss business highlights. Call details and dial-in are provided below.CardiAMP autologous cell therapy in ischemic heart failure of reduced ejection fraction . In parallel to advancing the regulatory discussions with the USA FDA and Japan PMDA on the potential market release of the CardiAMP System for the treatment of ischemic heart failure, we are advancing the confirmatory CardiAMP HF II Trial.clinical study began at University of Wisconsin at Madison and Henry Ford. Health System in Detroit MI, respectively. Emory Univers","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4099","BK4585","BK4588","03160","R","BK4555","BK4604","TM","LABU","BK4139","BK4022","BCDA"],"gpt_icon":0},{"id":"2620738459","title":"BioCardia Inc  expected to post a loss of 17 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738459","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738459?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:35","pubTimestamp":1774006505,"startTime":"0","endTime":"0","summary":"BioCardia Inc  expected to post a loss of17cents a share - Earnings Preview BioCardia Inc BCDA.OQ BCDA.O is expected to  show no change in quarterly revenue when it reports  results on March 24 for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4080XO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2620277414","title":"BioCardia Inc. to host 2025 financial results and corporate update conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277414","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277414?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:48","pubTimestamp":1773964086,"startTime":"0","endTime":"0","summary":"BioCardia will host a financial results and corporate update conference call on March 24, 2026 at 4:30 PM EDT.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL4qsTsP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","SG9999014021.USD","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014039.USD","BK4588","LU2095319765.USD","BK4112","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDA","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","SG9999014013.SGD","IE00BN0W2W23.USD"],"gpt_icon":0},{"id":"2620277449","title":"BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277449","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277449?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:47","pubTimestamp":1773964020,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., March  19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259518/0/en/BioCardia-to-Host-2025-Financial-Results-and-Corporate-Update-Conference-Call-on-March-24-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4181","HST","BK4588","BK4585","BK4139","BK4218"],"gpt_icon":0},{"id":"2620425631","title":"BioCardia Advances Helix Catheter Toward FDA Marketing Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2620425631","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620425631?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:32","pubTimestamp":1773743550,"startTime":"0","endTime":"0","summary":"BioCardia ( ($BCDA) ) has provided an announcement. On March 17, 2026, BioCardia announced that the U.S. Food and Drug Administration accepted its ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-advances-helix-catheter-toward-fda-marketing-clearance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-advances-helix-catheter-toward-fda-marketing-clearance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BCDA","BK4585","BK4139","LABU"],"gpt_icon":0},{"id":"2620280694","title":"FDA accepts BioCardia Helix catheter pre-submission package","url":"https://stock-news.laohu8.com/highlight/detail?id=2620280694","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620280694?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:01","pubTimestamp":1773741707,"startTime":"0","endTime":"0","summary":"BioCardia said the FDA accepted its pre-submission package seeking approval of the Helix transendocardial delivery catheter for intramyocardial delivery of therapeutic and diagnostic agents. The company said it has held preliminary meetings with the FDA’s CDRH and CBER, with CDRH expected to lead the review in consultation with CBER. BioCardia said CDRH acknowledged the CBER CardiAMP Cell Therapy Breakthrough Designation enabled by Helix.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9sfKDf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","LU2095319765.USD","NDAQ","BCDA","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014021.USD","BK4139","LU0314104364.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","BK4112","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014039.USD"],"gpt_icon":0},{"id":"2616323691","title":"BioCardia Highlights Positive CardiAMP Phase III Heart Failure Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2616323691","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616323691?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:39","pubTimestamp":1772545157,"startTime":"0","endTime":"0","summary":"BioCardia ( ($BCDA) ) has issued an announcement. On March 3, 2026, BioCardia reported late-breaking echocardiography data from its Phase III Cardi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-highlights-positive-cardiamp-phase-iii-heart-failure-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-highlights-positive-cardiamp-phase-iii-heart-failure-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["III","BK4139","BK4134","BCDA"],"gpt_icon":0},{"id":"2616340039","title":"BioCardia reports late-breaking CardiAMP HF echocardiography results at THT 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340039?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:02","pubTimestamp":1772542954,"startTime":"0","endTime":"0","summary":"BioCardia Inc. reported late-breaking echocardiography results from its Phase III CardiAMP HF trial in ischemic heart failure with reduced ejection fraction. The company said core-lab echocardiography measurements showed reduced negative left ventricular remodeling over time in treated patients versus controls, with statistically significant differences in left ventricular end-diastolic and end-systolic volumes in a prespecified subgroup with elevated NT-proBNP. The results were presented at the Technology and Heart Failure Therapeutics  meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL9kydJm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2616404513","title":"BioCardia Late Breaking Echocardiography Clinical Results From Cardiamp HF Trial Presented at Technology and Heart Failure Therapeutics (Tht)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616404513","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616404513?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542806,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA6TD82W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2610297826","title":"BioCardia Advances FDA Pathway for Helix Delivery Catheter","url":"https://stock-news.laohu8.com/highlight/detail?id=2610297826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610297826?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:53","pubTimestamp":1770735209,"startTime":"0","endTime":"0","summary":"BioCardia ( ($BCDA) ) has issued an announcement. On February 10, 2026, BioCardia reported it had completed a Pre-Submission to the U.S. Food and D...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-advances-fda-pathway-for-helix-delivery-catheter?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-advances-fda-pathway-for-helix-delivery-catheter?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2610626333","title":"BioCardia Submits Pre-Submission to FDA for Helix Transendocardial Delivery Catheter Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2610626333","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610626333?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:15","pubTimestamp":1770732928,"startTime":"0","endTime":"0","summary":"BioCardia Inc. has completed a Pre-Submission to the U.S. Food and Drug Administration  under its Q-Submission program for the approval of its Helix Transendocardial Delivery Catheter. The Helix catheter is intended for intramyocardial therapeutic and diagnostic agent delivery to the heart. The submission is supported by data from fifteen well-controlled clinical trials across three primary cardiac clinical indications. The Pre-Submission was made under the CardiAMP Cell Therapy System FDA Breakthrough Designation. BioCardia is seeking to align with the FDA on the regulatory pathway and timing for approval, with a potential application for market clearance expected to follow.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLtR0Bg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014005.SGD","NDAQ","BCDA","IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","BK4588","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014039.USD","BK4112"],"gpt_icon":0},{"id":"2608908879","title":"BioCardia Unveils Late-Breaking CardiAMP HF Trial Echocardiography Results at THT Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2608908879","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608908879?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:02","pubTimestamp":1770123734,"startTime":"0","endTime":"0","summary":"BioCardia Inc. has announced that late breaking echocardiography results from the CardiAMP HF Trial will be presented at the Technology and Heart Failure Therapeutics  Meeting, scheduled for March 2-4 in Boston, Massachusetts. The presentation, titled \"Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF trial,\" will be delivered by Dr. Amish Raval, M.D., on March 2 at 2pm EST. The data concerns the use of CardiAMP Cell Therapy for the treatment of heart failure. The results have not yet been presented and are scheduled for future disclosure at the THT Meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL2Br2Sb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2608879840","title":"BioCardia Announces Late Breaking Echocardiography Results From the Cardiamp HF Trial to Be Presented at Technology and Heart Failure Therapeutics (Tht)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879840?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUA81LVZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2605350054","title":"BioCardia CEO Peter Altman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605350054","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605350054?lang=en_us&edition=fundamental","pubTime":"2026-01-22 06:03","pubTimestamp":1769033038,"startTime":"0","endTime":"0","summary":"Peter Altman, President and CEO of BioCardia Inc., reported a disposal of common shares of BioCardia Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL9Gn3VB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioCardia CEO Peter Altman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2592941514","title":"BioCardia CEO Peter Altman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592941514","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592941514?lang=en_us&edition=fundamental","pubTime":"2025-12-18 07:33","pubTimestamp":1766014395,"startTime":"0","endTime":"0","summary":"Peter Altman, President and CEO of BioCardia Inc., reported a disposal of common shares of BioCardia Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLbjyPKy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioCardia CEO Peter Altman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2591825579","title":"BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2591825579","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591825579?lang=en_us&edition=fundamental","pubTime":"2025-12-16 21:00","pubTimestamp":1765890000,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Dec.  16, 2025  (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/16/3206152/0/en/BioCardia-Cell-Therapy-for-Ischemic-Heart-Failure-to-Progress-to-Formal-Clinical-Consultation-with-Japan-PMDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU2500361329.USD","LU0661504455.SGD","LU2637428348.USD","LU2065732104.USD","CMS","LU0949170772.SGD","LU1003077747.HKD","LU2346227817.USD","LU0553294199.USD","BK4157","BK4585","BK4588","BK4183","BCDA","LU0738911758.USD","PRGS","BK4208","MACE","LU0545039389.USD","LU1894683264.USD","LU1894683348.USD","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":0.0129},{"period":"3month","weight":-0.0709},{"period":"6month","weight":-0.169},{"period":"1year","weight":-0.5373},{"period":"ytd","weight":-0.056}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.0655},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1345},{"period":"ytd","weight":-0.054}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.066663},{"month":2,"riseRate":0.5,"avgChangeRate":-0.017269},{"month":3,"riseRate":0.25,"avgChangeRate":-0.025282},{"month":4,"riseRate":0.428571,"avgChangeRate":0.016522},{"month":5,"riseRate":0.375,"avgChangeRate":-0.084107},{"month":6,"riseRate":0.25,"avgChangeRate":-0.048165},{"month":7,"riseRate":0.5,"avgChangeRate":-0.016411},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102769},{"month":9,"riseRate":0.375,"avgChangeRate":0.008782},{"month":10,"riseRate":0.375,"avgChangeRate":-0.049332},{"month":11,"riseRate":0.5,"avgChangeRate":0.042585},{"month":12,"riseRate":0.375,"avgChangeRate":-0.012187}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction